MARKET

SNGX

SNGX

Soligenix Inc
NASDAQ
0.6071
+0.0171
+2.90%
After Hours: 0.5960 -0.0111 -1.83% 17:51 03/27 EDT
OPEN
0.6000
PREV CLOSE
0.5900
HIGH
0.6119
LOW
0.6000
VOLUME
166.03K
TURNOVER
0
52 WEEK HIGH
4.200
52 WEEK LOW
0.3800
MARKET CAP
6.39M
P/E (TTM)
-0.7670
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SNGX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at SNGX last week (0311-0315)?
Weekly Report · 03/18 10:18
SNGX Stock Earnings: Soligenix Beats EPS, Beats Revenue for Q4 2023
Soligenix reported earnings per share of -6 cents. The company reported revenue of $205,453. This was 2.73% better than the analyst estimate of $200,000. Soligenix is down 2.7% after the market closed on Wednesday.
Investorplace · 03/15 17:53
Recap: Soligenix Q4 Earnings
Soligenix reported its Q4 earnings on March 15. The company beat estimates by 68.0%. Soligenix's revenue was down $160 thousand from the same period last year. The stock fell 1.0% after the announcement. Soligenx is expected to report its earnings on Friday morning.
Benzinga · 03/15 13:35
Soligenix FY GAAP EPS $(0.79) Beats $(0.82) Estimate, Sales $800.00K Beat $797.50K Estimate
Soligenix reported quarterly losses of $0.79 per share. The company reported quarterly sales of $800.00 thousand. Soligenix beat the analyst consensus estimate of $797.50 thousand by 3.66%. The company also reported quarterly revenues of $900.000 thousand.
Benzinga · 03/15 11:36
Soligenix GAAP EPS of -$0.79
Seeking Alpha · 03/15 11:35
*Soligenix Cash Position Was $8.4M at Dec 31 >SNGX
Dow Jones · 03/15 11:31
Press Release: Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results for the year ended December 31, 2023. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company's primary focus in 2024 is advancing its clinical programs.
Dow Jones · 03/15 11:30
More
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Webull offers Soligenix Inc stock information, including NASDAQ: SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNGX stock methods without spending real money on the virtual paper trading platform.